{"id":"intramuscular-olanzapine-depot","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Weight gain"},{"rate":"20-30","effect":"Sedation"},{"rate":"15-25","effect":"Hyperglycemia"},{"rate":"15-20","effect":"Hyperlipidemia"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"5-10","effect":"Akathisia"},{"rate":"5-10","effect":"Extrapyramidal symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to mood stabilization and reduction of negative symptoms. The depot formulation provides sustained drug release over weeks to months, improving medication adherence in chronic psychiatric conditions.","oneSentence":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:44.117Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia maintenance treatment"},{"name":"Bipolar I disorder maintenance treatment"}]},"trialDetails":[{"nctId":"NCT00320489","phase":"PHASE3","title":"Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-04","conditions":"Schizophrenia","enrollment":524},{"nctId":"NCT00088465","phase":"PHASE3","title":"Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-08","conditions":"Schizophrenic Disorders, Schizoaffective Disorder","enrollment":931},{"nctId":"NCT01389908","phase":"NA","title":"A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder","status":"UNKNOWN","sponsor":"Shalvata Mental Health Center","startDate":"2011-06","conditions":"Schizophrenia, Schizoaffective Disorders","enrollment":2},{"nctId":"NCT00236457","phase":"PHASE3","title":"A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2000-11","conditions":"Schizophrenia, Psychotic Disorders","enrollment":629},{"nctId":"NCT00088491","phase":"PHASE3","title":"Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-06","conditions":"Schizophrenic Disorders","enrollment":1205},{"nctId":"NCT00088478","phase":"PHASE3","title":"Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-06","conditions":"Schizophrenia","enrollment":402},{"nctId":"NCT00094640","phase":"PHASE1","title":"Pharmacokinetic Characterization of Intramuscular Olanzapine Depot","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY170053","Zyprexa Adhera"],"phase":"phase_3","status":"active","brandName":"Intramuscular Olanzapine Depot","genericName":"Intramuscular Olanzapine Depot","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia maintenance treatment, Bipolar I disorder maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}